CDK4 and cancer: Thus, the molecular mechanisms by which CDK4/6 inhibitors induce senescence in cancer cells and the genes involved in conferring drug resistance or lack of response to these inhibitors are unknown, preventing patient stratification prior to Palbociclib treatment [18].